Gilder Gagnon Howe & Co. LLC Has $22.38 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Gilder Gagnon Howe & Co. LLC boosted its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 5,636.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 404,237 shares of the company's stock after buying an additional 397,190 shares during the quarter. Gilder Gagnon Howe & Co. LLC owned approximately 1.06% of Tarsus Pharmaceuticals worth $22,383,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Crowley Wealth Management Inc. bought a new stake in Tarsus Pharmaceuticals in the fourth quarter valued at about $25,000. R Squared Ltd bought a new position in shares of Tarsus Pharmaceuticals during the fourth quarter valued at approximately $53,000. HighTower Advisors LLC acquired a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $207,000. Summit Investment Advisors Inc. raised its position in shares of Tarsus Pharmaceuticals by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after purchasing an additional 244 shares during the period. Finally, Victory Capital Management Inc. acquired a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $223,000. 90.01% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. HC Wainwright reiterated a "buy" rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Jefferies Financial Group increased their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. Barclays dropped their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Guggenheim reiterated a "buy" rating and set a $78.00 price target (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Finally, Oppenheimer raised their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $63.67.

Insider Transactions at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 8,534 shares of Tarsus Pharmaceuticals stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $427,638.74. Following the transaction, the chief executive officer now owns 53,635 shares in the company, valued at approximately $2,687,649.85. The trade was a 13.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Dianne C. Whitfield sold 2,137 shares of the firm's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $50.11, for a total value of $107,085.07. Following the sale, the insider now owns 46,355 shares of the company's stock, valued at $2,322,849.05. The trade was a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,542 shares of company stock valued at $1,581,173 in the last three months. 8.25% of the stock is currently owned by corporate insiders.

Tarsus Pharmaceuticals Stock Performance

TARS traded down $0.28 during trading hours on Monday, hitting $49.72. The company's stock had a trading volume of 685,350 shares, compared to its average volume of 689,959. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $20.08 and a fifty-two week high of $57.28. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The firm has a market capitalization of $1.91 billion, a PE ratio of -13.05 and a beta of 0.94. The company has a 50-day simple moving average of $47.60 and a 200 day simple moving average of $48.53.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.68) by $0.08. The firm had revenue of $66.41 million during the quarter, compared to analyst estimates of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. As a group, sell-side analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.